An interventional study of WeChat mini-program "Epilepsy Smart Monitoring System" in Epilepsies and Remote Management of Epilepsy in Rural Areas, sponsored by Xijing Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Xijing Hospital · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Epilepsy with a site in China — 35 open to participants now, 41 under way, 5 of them phase 3. Epilepsy · China.
Among the 101 studies in Epilepsy with a site in China, this one is the 54th largest by planned enrollment of the 64 interventional ones that give a count, is one of 9 that started in 2025, is one of 21 with no phase, reaches primary completion later than 33 of the 40 other live ones, and was the 92nd registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →35 of the 101 studies in Epilepsy with a site in China are open now. Recruiting first, the newest first:
Boston Scientific Corporation · Sites in China
Ages 18–65
Shanghai UniXell Biotechnology Co., Ltd · Sites in China
Ages 18–75
Xuanwu Hospital, Beijing · Sites in China
Ages 18–60
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Sites in China
Ages 18+ · Women only · Healthy volunteers
Xijing Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 6 · Phase 3 23 · Phase 4 5
First in 2006; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 141 across the 64 interventional studies, 234 across the 37 observational. Of the 37 that completed or were terminated, 22 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 101 have an industry lead sponsor. The 10 most frequent:
Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
Xijing Hospital has 8 studies filed under Epilepsy — fewer than ten, so there is no comparison to draw.
14 of the studies in Epilepsy with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT07095933Xuanwu Hospital, BeijingThe Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy | 2026-12-01 |
| NCT03822741Children's Hospital of Fudan UniversityEtiology and Treatment of Neonatal Seizure | 2026-12-30 |
| NCT04917939Second Affiliated Hospital, School of Medicine, Zhejiang UniversityGene Expression Changes of Brain Tissue in Human Temporal Lobe Epilepsy With Hippocampal Sclerosis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 101 studies in Epilepsy with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project, titled " Research on the Application of Mobile Health Management Mini-Programs in Long-Term Management of Epilepsy in Rural Areas", is led by the First Affiliated Hospital of Air Force Medical University, with Jiang Wen as the principal investigator. It is a prospective, multicenter, cluster-randomized controlled trial involving 1276 patients from eight rural counties in China's northwest region. This study aims to establish a new scheme for improving epilepsy management in rural areas of Northwest China by combining remote mobile health management technology. The primary objective is to evaluate the effectiveness of the remote medical management model using a mobile health management mini-program in improving the self-management ability of rural epilepsy patients; secondary objectives include evaluating the impact of this model on patients' medication adherence, quality of life, health status, and frequency of epileptic seizures. Key components include patient and doctor interfaces for features like medication reminders, and seizure records. The trial runs from December 1, 2025, to November 30, 2028, with primary outcomes measured at 6 and12 months and secondary outcomes assessing medication adherence, quality of life, and safety.
The criteria were revised on the registry on Nov 18, 2026. See what changed
Patient inclusion criteria:
Patient exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: WeChat mini-program "Epilepsy Smart Monitoring System"
Patient Module: Real-time monitoring, medication reminders, seizure logging, educational resources. Physician Module: remote follow-up, data analytics dashboard.
Epilepsy Self Management Scale Score
Evaluation method: The Chinese version of the Epilepsy Self Management Scale was used. This scale includes multiple dimensions (such as drug management, information management, safety management, etc.), and a higher total score indicates stronger self-management ability.
Time frame: 6 and 12 months
Plan to share: No — IPD will not be shared due to privacy constraints, contractual agreements.
Started Dec 2025 (actual). Primary completion is estimated for Nov 2028, 35 months after the start.
Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 35 months is below that.
Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Nov 2027 → Nov 2028 and completion Nov 2027 → Nov 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.